The Global Multiple Sclerosis Market 2009-2024

• Publication date: 19/03/2009

• Number of Pages: 128

1. Report Details
2. Table of Contents
3. Companies Listed

Report Details

Global Multiple Sclerosis Market will expand steadily from 2009 to 2024 - new
report explains

The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those
revenues will exceed $9bn during the second half of next decade, our new study shows.
The World Health Organization estimates that over 2.5 million people suffer from
multiple sclerosis worldwide. The prevalence and onset of MS in children and adults is
expected to rise steadily. Global sales for MS therapies will rise accordingly, due to
epidemiological, healthcare and commercial drivers. In this new market-based study -
The Global Multiple Sclerosis Market 2009-2024 – we show and explain those trends in
detail. This report will provide you with the analytical information that you need to
understand current trends and future directions in the MS market area, the successful
drugs being introduced and where the future successful growth of the market lies.

The Global Multiple Sclerosis Market 2009-2024 commercially analyses both leading
and emergent treatments, with key companies and products discussed comprehensively.
In particular, we discuss prospects for the following MS drugs:
- Tysabri
- Avonex
- Copaxone
- Betaferon
- Rebif.

Contemporary disease-modifying drugs for MS are administered intravenously,

intramuscularly or subcutaneously, typically with discomfort to patients. We believe that
orally-administered MS products will change the dynamics of the market area
significantly. But you must understand now the commercial opportunities for those new
agents and other exciting pipeline developments. This report answers those important
questions and others, such as how the established MS products will fare competitively in
the years ahead. Which will remain the most profitable and how will they be effected by
new competition.

Comprehensive Market Analysis

The Global Multiple Sclerosis Market 2009-2024 examines the market sector critically
through a comprehensive review of information sources, including first-hand primary
consultations with relevant experts. This report provides detailed sales forecasts,
discussions of pipeline developments and analyses of important contemporary issues,
especially relevant commercial drivers and restraints. Sources used include gold-standard
commercial databases, in-house analytical tool, industry news, published reports, policy
documents and economic research. Importantly, visiongain applies rigorous financial
forecasting, qualitative analyses and the assessment of unmet needs. The result is a
comprehensive market- and industry-centred report with detailed analysis and informed
opinion.

Why you should buy The Global Multiple Sclerosis Market 2009-2024
By purchasing this report, you will receive the following benefits:
• Predicted revenues, growth rates and other key metrics for the global MS drugs market
from 2009 to 2024
• Predicted revenues, growth rates and other key metrics for leading MS drugs worldwide
from 2009 to 2024
• Predicted revenues, growth rates and other key metrics for MS drug sales in leading
nations from 2009 to 2024
• Expert opinions from original visiongain interviews, with full interview transcripts –
you will not find this information anywhere else
• Discussion of hot pipeline developments and up-and-coming products
• Discussion of forces that influence and characterise the market for MS treatments
worldwide:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats
• Discussion of where the market is heading overall - both technologically and
commercially - from the present onwards.

Nobody with an interest in the MS sector can afford to overlook this new market study
from visiongain. Visiongain predicts that total revenues in the MS market will increase
steadily throughout the forecast period, 2009 to 2024, with the most substantial growth
occurring during a crucial period in the future. The market environment in many
countries will change, with patent losses affecting current market leaders in MS
treatment. New drug releases and reformulations of products will seek to increase
therapeutic effectiveness, especially patient compliance. A new wave of oral drugs,
currently in development, may well change the way MS treatments are delivered. Do you
want to know more about this important market? You must order this report today.
Visiongain ltd.
4th Floor,
BSG House,
226 236 City Road,
London
EC1V 2QY
United Kingdom

Telephone: +44 (0) 20 7336 6100

Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com/Report.aspx?rid=374
Or http://www.visiongain.com

Or
Contact Person

Suvitha Damodaran
suvitha.damodaran@visiongainglobal.com
Direct Line: +44 (0)20 7549 9946
+44 (0)20 7336 6100